pubmed.ncbi.nlm.nih.gov

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials - PubMed

️Tue Jan 01 2008

Review

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

Asquad Sultan et al. BMC Neurol. 2008.

Abstract

Background: Duloxetine hydrochloride is a reuptake inhibitor of 5-hydroxytryptamine and norepinephrine used to treat depression, generalized anxiety disorder, neuropathic pain, and stress incontinence in women. We investigated the efficacy of duloxetine in painful diabetic neuropathy and fibromyalgia to allow comparison with other antidepressants.

Methods: We searched PubMed, EMBASE (via Ovid), and Cochrane CENTRAL up to June 2008 for randomised controlled trials using duloxetine to treat neuropathic pain.

Results: We identified six trials with 1,696 patients: 1,510 were treated with duloxetine and 706 with placebo. All patients had established baseline pain of at least moderate severity. Trial duration was 12 to 13 weeks. Three trials enrolled patients with painful diabetic neuropathy (PDN) and three enrolled patients with fibromyalgia. The number needed to treat (NNT) for at least 50% pain relief at 12 to 13 weeks with duloxetine 60 mg versus placebo (1,211 patients in the total comparison) was 5.8 (95% CI 4.5 to 8.4), and for duloxetine 120 mg (1,410 patients) was 5.7 (4.5 to 5.7). There was no difference in NNTs between PDN and fibromyalgia. With all doses of duloxetine combined (20/60/120 mg) there were fewer withdrawals for lack of efficacy than with placebo (number needed to treat to prevent one withdrawal 20 (13 to 42)), but more withdrawals due to adverse events (number needed to harm (NNH) 15 (11 to 25)). Nausea, somnolence, constipation, and reduced appetite were all more common with duloxetine than placebo (NNH values 6.3, 11, 11, and 18 respectively). The results for duloxetine are compared with published data for other antidepressants in neuropathic pain.

Conclusion: Duloxetine is equally effective for the treatment of PDN and fibromyalgia, judged by the outcome of at least 50% pain relief over 12 weeks, and is well tolerated. The NNT of 6 for 50% pain relief suggests that this is likely to be a useful drug in these difficult-to-treat conditions, where typically only a minority of patients respond. Comparing duloxetine with antidepressants for pain relief in DPN shows inadequacies in the evidence for efficacy of antidepressants, which are currently recommended in PDN care pathways.

PubMed Disclaimer

Figures

**Figure 1**
Proportion of patients with at least 50% pain relief with duloxetine 60 mg or 120 mg and placebo in individual trials. Pink circles are fibromyalgia trials. Inset scale shows number in comparison.

**Figure 2**
Mean change from baseline to endpoint on the 24-hour average pain score (APS) for treatment compared to placebo over 12 to 13 weeks, by duloxetine dose (60 mg and 120 mg) and condition (diabetic neuropathy and fibromyalgia).

Cited by

The Interrelationship between Diabetes Mellitus and Emotional Well-Being: Current Concepts and Future Prospects.
Mangoulia P, Milionis C, Vlachou E, Ilias I. Mangoulia P, et al. Healthcare (Basel). 2024 Jul 22;12(14):1457. doi: 10.3390/healthcare12141457. Healthcare (Basel). 2024. PMID: 39057600 Free PMC article. Review.
Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response.
Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, McQuay HJ. Straube S, et al. BMC Musculoskelet Disord. 2011 Jun 3;12:125. doi: 10.1186/1471-2474-12-125. BMC Musculoskelet Disord. 2011. PMID: 21639874 Free PMC article.
Gabapentin for chronic neuropathic pain and fibromyalgia in adults.

Moore RA, Wiffen PJ, Derry S, McQuay HJ. Moore RA, et al. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007938. doi: 10.1002/14651858.CD007938.pub2. Cochrane Database Syst Rev. 2011. PMID: 21412914 Free PMC article. Updated. Review.
Imipramine for neuropathic pain in adults.
Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Hearn L, et al. Cochrane Database Syst Rev. 2014 May 19;2014(5):CD010769. doi: 10.1002/14651858.CD010769.pub2. Cochrane Database Syst Rev. 2014. PMID: 24838845 Free PMC article. Review.
[Diabetic neuropathy and diabetic foot syndrome (update 2023)].
Köhler G, Eichner M, Abrahamian H, Kofler M, Sturm W, Menzel A. Köhler G, et al. Wien Klin Wochenschr. 2023 Jan;135(Suppl 1):164-181. doi: 10.1007/s00508-023-02167-7. Epub 2023 Apr 20. Wien Klin Wochenschr. 2023. PMID: 37101039 Free PMC article. German.

References

1. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007;68:1178–1182. doi: 10.1212/01.wnl.0000259085.61898.9e. - DOI - PubMed
1. Jadad AR, Carroll D, Glynn CJ, Moore RA, McQuay HJ. Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia. Lancet. 1992;339:1367–1371. doi: 10.1016/0140-6736(92)91194-D. - DOI - PubMed
1. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ. 1995;311:1047–1052. - PMC - PubMed
1. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain. 1996;68:217–227. doi: 10.1016/S0304-3959(96)03140-5. - DOI - PubMed
1. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P, EFNS Task Force EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153–1169. doi: 10.1111/j.1468-1331.2006.01511.x. - DOI - PubMed

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials - PubMed